CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme , small cell lung cancer and ovarian cancer . Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin.